Clinical Trial

Bone Health After Bariatric Surgery in Patients With Type 2 Diabetes

Study acronym: BODI
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated June 10, 2025 (before its estimated December 1, 2025 completion). Its status may not reflect the trial's current state.
Summary
Background: Bone fragility is a complication of type 2 diabetes. Diabetes treatments may ameliorate or deteriorate bone fragility in this population. Bariatric surgery is gaining in popularity in people with type 2 diabetes and may impact bone health. Objectives: To evaluate the impact of the most popular bariatric procedure worldwide (sleeve gastrectomy (SG)) on vBMD by QCT in patients with type 2 diabetes; Secondary aims: (1) to identify the determinants of vBMD after bariatric surgery in patients with type 2 diabetes; (2) to compare vBMD and its potential determinants after bariatric surgery with obese controls without diabetes as well as with controls without obesity and normoglycemia.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2018-03-05; most recent amendment 2025-06-05.
Trial Details
NCT Number NCT03455868
Lead Sponsor CHU de Quebec-Universite Laval
Collaborators: McGill University Health Centre/Research Institute of the McGill University Health Centre
Conditions Bariatric Surgery, Bone Health, Obesity, Morbid, Diabetes Mellitus, Type 2
Enrollment 100 participants
Start Date 2018-03-15
Primary Completion 2025-12-01 (estimated)
Study Completion 2025-12-01 (estimated)
Updated on ClinicalTrials.gov 2025-06-10